Track market-moving stories before they get noisy

SummaryLennar Corporation trades at 0.83x book, well below peers, with Berkshire Hathaway now owning about 12% after significant recent purchases.I see fair value for LEN at $90–$100 per share, supported by long-term U.S. housing shortages and Lennar’s asset-light, high-volume strategy.LEN faces near-term margin pressure (15.8% Q3 gross margin), high mortgage rates, and governance questions regarding related-party sales to Millrose.Despite risks, LEN’s balance sheet, scale, and patient capital position it for recovery; current valuation already discounts substantial negative sentiment. JHVEPhoto/iStock Editorial via Getty Images

Lennar Corporation (LEN) closed at $74.44 on Monday, October 5, a new 52-week low and 44% below the $133.76 high. The stock now trades at about 0.83x book value, and it is the only large public homebuilder I follow priced

6.16K Followers

Analyst’s Disclosure: I/we have a beneficial long position in the shares of LEN either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

LONG BEACH, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- California Resources Corporation (NYSE: CRC) plans to release its third quarter 2026 financial results on Monday, November 2nd after market hours. The Company will hold a conference call to discuss these financial results on Tuesday, November 3rd at 1:00 p.m. Eastern Time (10:00 a.m. Pacific Time).

We encourage participants to pre-register for the conference call using the following link: https://dpregister.com/sreg/10211602/104c2aa7a86. Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time.

To participate in CRC’s conference call, either dial (877) 328-5505 (International callers please dial +1-412-317-5421) or access the webcast at www.crc.com. A digital replay of the conference call will be archived for approximately 90 days and available on the Investor Relations page at www.crc.com.

About California Resources Corporation

California Resources Corporation (CRC) is an independent energy and carbon management company advancing the energy transition. CRC is committed to environmental stewardship while safely providing local, responsibly sourced energy. CRC is also focused on maximizing the value of its land, mineral ownership, and energy expertise for decarbonization by developing carbon capture and storage and other emissions-reducing projects. For more information about CRC, please visit www.crc.com.

Contacts:  Daniel Juck
(Investor Relations)Hailey Bonus
(Media) 818-661-3700714-874-7732 [email protected]@crc.com 

Integration Advances ETF Infrastructure and Supports Long-Term Growth Strategy

, /PRNewswire/ -- SEI® (NASDAQ:SEIC) today announced it has entered into an agreement with Intercontinental Exchange, Inc. (NYSE:ICE), one of the world's leading providers of financial market technology and data powering global financial markets, to leverage ICE ETF Hub, an open architecture platform designed to bring efficiencies to the primary market workflow for exchange-traded products (ETPs). The integration will support the creation and redemption process for ETP issuers and further enhance the efficiency, scalability, and reliability of SEI's ETP order management capabilities.

Through ICE ETF Hub, SEI gains access to a platform that supports more efficient ETP primary market workflows through standardized connectivity, automated order management, and enhanced collaboration across the ETP ecosystem. The platform is designed to simplify the creation and redemption process across ETPs of numerous asset classes.

Commenting on the collaboration, Sean Lawlor, Head of Public Markets for SEI's Investment Managers business, said:

"As the ETP market continues to expand, issuers need servicing partners with the infrastructure and expertise to support growth and scale. Our integration with ICE ETF Hub strengthens the operational foundation of our ETP solutions and supports our long-term ETP strategy, giving us the scalability to respond to expanding ETP assets, increased trading volumes, evolving industry standards, and future market innovation. This allows us to focus continued investment on the differentiated capabilities, servicing excellence, and innovation that help our clients succeed in a highly competitive marketplace."

ICE ETF Hub currently connects more than 250 issuers, more than 55 authorized participants, and market makers, and supports more than 1,800 ETPs. The platform surpassed $5 trillion in cumulative notional volume processed as of the second quarter of 2026, demonstrating its broad adoption and scale across the ETP industry.

Peter Borstelmann, President of ICE Bonds at Intercontinental Exchange, Inc., added:

"We're pleased to support SEI as it enhances its ETP servicing infrastructure and continues to scale its capabilities for investment managers. By bringing greater automation, standardization, and connectivity to ETP primary market workflows, ICE ETF Hub helps firms reduce operational complexity, manage liquidity, and improve efficiencies across the ETP ecosystem."

About SEI®
SEI (NASDAQ:SEIC) is a leading global provider of financial technology, operations, and asset management services within the financial services industry. SEI tailors its solutions and services to help clients more effectively deploy their capital—whether that's money, time, or talent—so they can better serve their clients and achieve their growth objectives. As of June 30, 2026, SEI manages, advises, or administers approximately $2.1 trillion in assets. For more information, visit seic.com.

About Intercontinental Exchange
Intercontinental Exchange, Inc. (NYSE: ICE) is a Fortune 500 company that designs, builds, and operates digital networks that connect people to opportunity. We provide financial technology and data services across major asset classes, helping our customers access mission-critical workflow tools that increase transparency and efficiency. ICE's futures, equity, and options exchanges -- including the New York Stock Exchange -- and clearing houses help people invest, raise capital and manage risk. We offer some of the world's largest markets to trade and clear energy and environmental products. Our fixed income, data services and execution capabilities provide information, analytics and platforms that help our customers streamline processes and capitalize on opportunities. At ICE Mortgage Technology, we are transforming U.S. housing finance, from initial consumer engagement through loan production, closing, registration and the long-term servicing relationship. Together, ICE transforms, streamlines, and automates industries to connect our customers to opportunity.

Trademarks of ICE and/or its affiliates include Intercontinental Exchange, ICE, ICE block design, NYSE and New York Stock Exchange. Information regarding additional trademarks and intellectual property rights of Intercontinental Exchange, Inc. and/or its affiliates is located here. Key Information Documents for certain products covered by the EU Packaged Retail and Insurance-based Investment Products Regulation can be accessed on the relevant exchange website under the heading "Key Information Documents (KIDS)."

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 -- Statements in this press release regarding ICE's business that are not historical facts are "forward-looking statements" that involve risks and uncertainties. For a discussion of additional risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see ICE's Securities and Exchange Commission (SEC) filings, including, but not limited to, the risk factors in ICE's Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the SEC on February 5, 2026.

Forward-looking statements
This communication contains forward-looking statements within the meaning of the rules and regulations of the Securities and Exchange Commission. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "expect," "believe," "can," "continue," "seek," or similar expressions.

SEI's forward-looking statements include its current expectations as to:

the potential benefits of SEI's integration with ICE ETF Hub, including enhanced efficiency, scalability, reliability, automation, standardization, and connectivity; SEI's ability to support expanding ETP assets, increased trading volumes, evolving industry standards, and future market innovation; and SEI's ability to execute its long-term ETP strategy and continue investing in differentiated capabilities, servicing excellence, and innovation. You should not place undue reliance on any forward-looking statements, as they are based on the current beliefs and expectations of management and are subject to significant risks and uncertainties, many of which are beyond management's control or are subject to change. Although management believes the assumptions upon which the forward-looking statements are based are reasonable, they could be inaccurate. Some of the risks and important factors that could cause actual results to differ from those described in SEI's forward-looking statements can be found in the "Risk Factors" section of SEI's Annual Report on Form 10-K for the year ended Dec. 31, 2025, filed with the Securities and Exchange Commission. SEI undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Company Contact:          

Media Contacts:

Alicia Rudd

Valerie Kerner

SEI

Vested

+1 610-676-3887

+1 518-821-7555

[email protected] 

[email protected] 

Hannah Bizick

ICE

+1 941 387 4449

[email protected]

[email protected]

SOURCE SEI Investments Company

First-of-its-kind effort to close the gap between the benefits Veterans have earned and the benefits they receive

, /PRNewswire/ -- CLEAR (NYSE: YOU), the secure identity company, announced today that the U.S. Department of Veterans Affairs (VA) has integrated CLEAR1, CLEAR's secure identity platform, as part of a pilot to reimagine the Veteran experience across digital and physical touchpoints. The pilot provides a new, fast, simple, and secure way for Veterans to create or access their VA.gov account—online or in person at select VA Medical Centers.

VA serves a community of roughly 17 million living U.S. Veterans and operates the nation's largest integrated health care system, serving 9.1 million enrolled Veterans each year. VA.gov is the critical digital connection to the care, benefits and services Veterans have earned, but that connection begins with the ability to create and access a VA.gov account. As part of VA's broader modernization effort, the CLEAR1 pilot will make that first step simpler and more consistent, whether a Veteran begins online or at a VA facility.

Beginning today, Veterans can select CLEAR to create or access their VA.gov account. After a quick, one-time setup, future sign-ins take just seconds with a selfie. Veterans who prefer in-person support, do not have a smartphone, or face connectivity challenges can enroll with CLEAR Ambassadors using CLEAR Pods at six participating VA medical centers in Brooklyn, New York; Washington, D.C.; Palo Alto, California; Decatur, Georgia; Orlando, Florida; and San Juan, Puerto Rico.

Behind that experience, CLEAR1 uses multi-layered verification that combines biometrics, government-issued identification and trusted data sources to establish confidence in the person accessing the account. That assurance is increasingly important to combat fraud, waste, and abuse among benefit access. Federal agencies reported an estimated $186 billion in improper payments in fiscal year 2025 across 64 programs. At VA, the Government Accountability Office found that the Beneficiary Travel Program alone accumulated an estimated $1 billion in improper payments between 2018 and 2024, including confirmed cases of fraud. Verifying that the right person is receiving the right benefit is the first line of defense, and every dollar recovered is a dollar available to the roughly 17 million Veterans who deserve support and resources after their service.

In anticipation of the pilot's launch, CLEAR invited Veterans to test CLEAR's VA.gov sign-in experience and provide feedback. Cheffren C., a U.S. Army Veteran said: "My transition from military service to civilian life was tough, and the VA has been supportive of me as a veteran all along the way. I see the VA investing in this new technology with CLEAR, and that it's only going to bring these benefits to veterans and their families faster and easier. It's comforting to know the same technology and company I trust from travel is available for veterans accessing VA benefits."

"I use VA.gov for health care, and when I was first separating, I was logging into the website basically every week," said Erik B., a U.S. Navy Veteran who also tested CLEAR on VA.gov. "The sign-in experience with CLEAR is very easy to use. I had assumed there would be more steps or paperwork needed, so I was very impressed with how quick and easy it was. Often when signing in to systems, you have to keep track of different usernames and passwords. What I love about CLEAR is that all goes away. It's a much more seamless process."

Caryn Seidman Becker, CEO of CLEAR, said: "CLEAR's mission is to make experiences safer and easier by securely connecting people to their true identity. We're honored to work with the Department of Veterans Affairs to meet America's Veterans and their loved ones where they are. Veterans earned these benefits, it should be easy for them to access them. Secure identity is the front door to care, and when that door works seamlessly and securely, Veterans get served faster and taxpayer dollars go where they belong."

Verifying with CLEAR is free and optional. Veterans may continue using another sign-in method if they prefer, and choosing not to enroll will not affect their ability to access VA benefits or services. Veterans' personal health information will remain with VA; CLEAR does not receive or access it through the identity verification process.

CLEAR has spent more than 16 years building identity infrastructure for the most highly regulated, highest-stakes environments in the country, from airport security checkpoints to health care. With over 43 million members, CLEAR is the leader in secure identity for the moments that matter most.

CLEAR1 is being deployed across federal health and civilian agencies, and CLEAR is under contract with the Centers for Medicare & Medicaid Services to modernize identity verification on Medicare.gov. CLEAR1 is Full Service certified by Kantara Initiative for NIST IAL2/AAL2 for its standard remote, self-service enrollment flow.

CLEAR is committed to privacy done right. Members are always in control of their own information, and the company does not sell biometric or sensitive personal data. There is no cost for Veterans to use CLEAR to sign in to VA.gov, enrollment is voluntary, and Veterans who choose not to enroll will continue to be served through existing VA processes. The VA and CLEAR will consider expanding this offering pending the results of this pilot program.

About CLEAR

The mission of CLEAR, the secure identity company, is to strengthen security and create frictionless experiences. With over 43 million Members and a growing network of partners across the world, CLEAR's secure identity platform is transforming the way people live, work, and travel. Whether you are traveling, at the stadium, or on your phone, CLEAR connects you to the things that make you, you—making everyday experiences easier, more secure, and friction-free. CLEAR is committed to privacy done right. Members are always in control of their own information, and we do not sell biometric or sensitive personal data. For more information, visit clearme.com.

Forward-Looking Statements

This release may contain statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. This includes, without limitation, statements regarding the scope, duration, timing, and potential expansion of the CLEAR1 pilot with the U.S. Department of Veterans Affairs (VA), including the availability of online and in-person enrollment and participating VA medical centers; the expected benefits of the pilot for Veterans, including faster and simpler account creation and access on VA.gov; the deployment of CLEAR1 across federal health and civilian agencies, including under CLEAR's contract with the Centers for Medicare & Medicaid Services; the ability of CLEAR's identity verification technology to help combat fraud, waste, and abuse in federal benefit programs; and anticipated demand for CLEAR's secure identity platform in government and healthcare settings. Investors are cautioned that such forward-looking statements are not guarantees of future performance or results and involve risks and uncertainties, and that actual results, developments and events may differ materially from those in the forward-looking statements as a result of various factors, including the risk that the VA pilot may not be continued, expanded, or converted into a long-term contract; the risk that Veterans may not adopt CLEAR1 at anticipated rates, including because enrollment is voluntary, or that the pilot may not deliver the expected benefits; reliance on government procurement processes, funding, appropriations (including the risk of a government shutdown), and policy decisions; the ability of government customers to terminate, modify, or decline to renew contracts or pilots, including for convenience; the ability to maintain required certifications and regulatory compliance, including Kantara Initiative Full Service certification for NIST IAL2/AAL2; risks related to the collection, storage, and processing of biometric and personal data; competition in the identity verification market; the ability to successfully deploy CLEAR1 technology at scale across federal agencies; and those described in Clear Secure, Inc.'s filings with the Securities and Exchange Commission, including the sections titled "Risk Factors" in its Annual Report on Form 10-K. Forward-looking statements speak only as of the date of this release, and CLEAR disclaims any obligation to update any forward-looking statements contained herein except as required by law.

Media Contact: [email protected] 

SOURCE CLEAR

Marvell Technology, Inc. (NASDAQ:MRVL – Get Free Report) declared a quarterly dividend on Friday, September 25th. Shareholders of record on Friday, October 9th will be given a dividend of $0.06 per share by the semiconductor company on Thursday, October 29th. This represents a $0.24 dividend on an annualized basis and a yield of 0.1%. The ex-dividend date of this dividend is Friday, October 9th.

Marvell Technology has a payout ratio of 6.7% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect Marvell Technology to earn $5.44 per share next year, which means the company should continue to be able to cover its $0.24 annual dividend with an expected future payout ratio of 4.4%.

Marvell Technology Stock Performance Shares of MRVL stock opened at $287.01 on Wednesday. Marvell Technology has a 12 month low of $70.68 and a 12 month high of $329.88. The stock has a market cap of $251.68 billion, a PE ratio of 94.72, a price-to-earnings-growth ratio of 2.62 and a beta of 2.26. The company has a current ratio of 3.17, a quick ratio of 2.62 and a debt-to-equity ratio of 0.27. The company’s fifty day moving average price is $231.21 and its 200-day moving average price is $207.54.

Marvell Technology (NASDAQ:MRVL – Get Free Report) last released its earnings results on Thursday, August 27th. The semiconductor company reported $0.94 earnings per share for the quarter, topping analysts’ consensus estimates of $0.93 by $0.01. Marvell Technology had a net margin of 27.93% and a return on equity of 13.57%. The firm had revenue of $2.74 billion for the quarter, compared to the consensus estimate of $2.72 billion. During the same period in the prior year, the firm earned $0.67 EPS. The company’s revenue was up 36.5% compared to the same quarter last year. Marvell Technology has set its Q3 2027 guidance at 1.050-1.150 EPS. On average, equities analysts expect that Marvell Technology will post 3.05 EPS for the current fiscal year. Trending Headlines about Marvell Technology Here are the key news stories impacting Marvell Technology this week:

Positive Sentiment: Marvell raised its fiscal 2028 revenue target to approximately $20 billion, up from $18 billion previously and above the roughly $18.2 billion analyst consensus. Management attributed the increase to strong demand for AI data-center infrastructure and accelerating custom-chip activity. Marvell Lifts Its Sales Outlook on Strong AI Demand Positive Sentiment: The company forecast fiscal 2031 revenue of $70 billion to $90 billion, with the $80 billion midpoint substantially above Wall Street’s prior estimate of approximately $46.85 billion. The outlook implies significant expansion in adjusted operating profit if Marvell reaches its targeted margins. Marvell shares jump as AI chip demand drives bullish revenue outlook Positive Sentiment: Analysts responded favorably: Evercore ISI raised its price target to $433 and maintained a Buy rating, while Raymond James also reiterated its Buy rating. Citi kept its Buy rating but left its target at $275, indicating that analyst views remain broadly bullish but valuation expectations vary. Marvell Target Raised to $433 Neutral Sentiment: Fiscal 2027 revenue guidance of $12 billion matched consensus, suggesting the most powerful catalyst is the company’s longer-term AI growth opportunity rather than a near-term estimate revision. Marvell’s recent quarterly results also showed 36.5% year-over-year revenue growth and a modest EPS beat. Negative Sentiment: Investors face execution and valuation risks. Marvell’s shares trade at a high earnings multiple after a substantial year-to-date rally, while analysts have cited customer concentration and intense competition. Reported insider activity showed sales by several executives and no open-market purchases during the period reviewed. MRVL Stock Skyrockets: Should Investors Buy, Sell or Hold? Marvell Technology Company Profile (Get Free Report)

Marvell Technology, Inc (NASDAQ: MRVL) is a fabless semiconductor company that develops technologies for data infrastructure. Its products are used to move, process, store and secure data across cloud data centers, enterprise networks, telecommunications systems, automotive platforms and other communications applications.

The company’s portfolio includes custom application-specific integrated circuits, data processing and networking solutions, Ethernet products, storage controllers, optical and electro-optical components, and connectivity technologies.

Read More Five stocks we like better than Marvell Technology Allient’s Data Center and Defense Momentum Is Raising the Stakes Constellation Energy’s Google Deal Shows Why Nuclear Uprates Matter for AI Lamb Weston’s Turnaround Is Starting to Look Real These 3 Stocks Got the Most Love From Analysts in September

Receive News & Ratings for Marvell Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marvell Technology and related companies with MarketBeat.com's FREE daily email newsletter.

-

- FDA STAR pilot program aims to shorten the time from complete supplement submission to the action date to allow earlier patient access to therapies that address an unmet medical need

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the United States Food and Drug Administration (FDA) has granted plozasiran entry in the Split Real Time Application Review (STAR) pilot program in connection with Arrowhead’s upcoming supplemental new drug application (sNDA) for severe hypertriglyceridemia (sHTG). SHTG is a condition that significantly increases the risk of acute pancreatitis, which is associated with repeated hospital admissions and can be fatal.

We are committed to pursuing every potential opportunity to accelerate the process of bringing plozasiran to patients, and the FDA STAR Pilot program provides important benefits to sponsors with efficacy supplements.

Share The FDA STAR pilot program aims to shorten the time from the date of a complete sNDA submission to the action date for certain supplemental indications for already-approved drugs. To be granted entry in the STAR program, FDA must determine that clinical evidence from adequate and well-controlled investigation(s) indicates that the drug may demonstrate substantial improvement on a clinically relevant endpoint(s) over available therapies.

Once accepted into the STAR program, a supplemental application qualifies for a 6-month Priority Review compared to a 10-month standard review. In addition, FDA will generally target an “expedited review” for efficacy supplements in the STAR program, meaning an action at least 1 month before the Priority Review goal date is possible. The use of a Priority Review Voucher (PRV) is not necessary for programs that are granted entry in the STAR program, so Arrowhead retains the PRV previously purchased in August 2026.

“We are committed to pursuing every potential opportunity to accelerate the process of bringing plozasiran to patients, and the FDA STAR Pilot program provides important benefits to sponsors with efficacy supplements,” said Christopher Anzalone, Ph.D., President and CEO at Arrowhead. “In addition, earning Priority Review for plozasiran without the need to use a PRV gives us the option to redeploy our voucher for a future application or monetize it.”

Arrowhead is on schedule to submit a sNDA for plozasiran in sHTG to the FDA by year-end 2026 and plans to seek regulatory approval with additional global regulatory authorities thereafter. Plozasiran has received regulatory approval, as REDEMPLO®, in the United States, the European Union, China, Australia, and Canada as an adjunct to diet to reduce triglycerides in adults with genetically confirmed or clinically diagnosed familial chylomicronemia syndrome (FCS), which is the most severe form of sHTG.

About Severe Hypertriglyceridemia

Severe hypertriglyceridemia (sHTG) is characterized by triglyceride (TG) levels greater than 500 mg/dL, with the most severe form being familial chylomicronemia syndrome (FCS) where TGs typically exceed 880 mg/dL. SHTG significantly increases the risk of acute pancreatitis (AP), which can often include recurrent attacks requiring repeat hospital admissions and worsening outcomes. AP risk is proportional to the number, characteristics, and concentration of triglyceride rich lipoproteins (TRLs), particularly chylomicrons, and increases as TGs rise. Elevated TGs can also increase the risk of atherosclerotic cardiovascular disease (ASCVD). Limited treatment options exist to sustainably reduce TGs below guideline directed risk thresholds.

About REDEMPLO® (plozasiran)

REDEMPLO (plozasiran) is currently approved by the U.S. Food and Drug Administration, Health Canada, China’s National Medical Products Administration, the Australian Therapeutic Goods Administration, and by the European Commission as an adjunct to diet to reduce triglycerides for adults with FCS. REDEMPLO is the first and only siRNA treatment approved in these countries to be studied in both clinically diagnosed and genetically confirmed patients living with FCS.

REDEMPLO is designed to suppress the production of apolipoprotein C-III (APOC3), a protein produced in the liver that raises triglyceride levels by slowing their breakdown and clearance. By targeting APOC3 with sustained silencing, REDEMPLO delivers significant reductions in triglyceride levels. REDEMPLO is self-administered via subcutaneous injection once every three months.

REDEMPLO has been granted Orphan Medicinal Product Designation by the EMA for the treatment of patients with FCS, and Breakthrough Therapy Designation, Fast Track Designation, and Orphan Drug Designation by the U.S. FDA for the treatment of patients with FCS and was also granted Breakthrough Therapy designation by the U.S. FDA in severe hypertriglyceridemia.

Sanofi acquired the rights to develop and commercialize REDEMPLO in Greater China, with Arrowhead retaining rights to REDEMPLO in all geographies, outside of Greater China.

For more information about REDEMPLO, visit Our Medicines.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals (NASDAQ: ARWR) is a commercial-stage pharmaceutical company developing medicines that treat intractable diseases by silencing the genes that cause them, harnessing the natural RNA interference (RNAi) mechanism. The company has built a broad portfolio of clinical and commercial RNAi therapeutics through its industry-leading targeted RNAi molecule (TRiM™) platform, which can precisely silence genes in a wide range of cell types, including liver, lung, muscle, adipose, and central nervous system tissue. At Arrowhead, we rapidly advance potential best- and first-in-class RNAi treatments for diseases with significant unmet medical need, because every day matters to the patients we serve.

For more information, please visit www.arrowheadpharma.com, or follow us on X (formerly Twitter) at @ArrowheadPharma, LinkedIn, Facebook, and Instagram. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “hope,” “intend,” “plan,” “project,” “could,” “estimate,” “continue,” “target,” “forecast” or “continue” or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline, products or product candidate or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about our beliefs and expectations regarding the long-term impacts on patient health and the health care system; our beliefs and expectations regarding the pricing, value, or expected timing for availability of our drugs and drug candidates; and our beliefs and expectations around the potential uses and value of the TRiM™ platform. These statements are based upon our current expectations and speak only as of the date hereof. Actual results or outcomes may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties the safety and efficacy of our products and product candidates, pricing and reimbursement decisions related to our products, demand for our products, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

Source: Arrowhead Pharmaceuticals, Inc.

More News From Arrowhead Pharmaceuticals, Inc.

Back to Newsroom

 | Source: Progyny, Inc.

Expecting 1.2 Million New Covered Lives from Commitments to Date and Anticipated Remaining Decisions 

Reflects How Employers are Increasingly Turning to Solutions with a Proven Track Record of Delivering Savings, Total Cost Management and ROI

Progyny’s Solutions Creating Compelling Opportunities for Employers to Stem Impacts from Broader Medical Cost Inflation Trend While Maintaining or Expanding Coverage of Services Impactful to their Workforce

NEW YORK, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY) (“Progyny” or the “Company”), a global leader in women's health and family building solutions, today revealed key insights from the Company’s current annual selling season, based on both commitments received to date and anticipated remaining decisions which are expected to contribute 1.2 million new covered lives from launches throughout the first half of 2027.

Employers are now weighing how to best meet the complex needs of their workforce while simultaneously wrestling with the broader escalation in the overall medical cost trend. Progyny’s solutions are addressing very real and highly prevalent medical needs for women and families, making these categories particularly relevant to today’s workforce.

This season, Progyny is seeing the savviest and most data-intensive employers meet this challenge — whether or not they currently provide coverage for infertility — by leaning into those benefit managers, like Progyny, who have a proven history of mitigating that broader cost trend through programs that drive savings through a combination of superior clinical outcomes and effective total cost management.

“With the commitments we have received to date and anticipated remaining decisions, our selling season is pacing to a potential record level for new lives added for our managed fertility solution,” said Pete Anevski, Chief Executive Officer, Progyny. “We believe it isn’t coincidental that we’re seeing these strong results given the expected record increases in the overall medical plan cost in 2027.”

While buyers continue to be focused on cost, quality, and member experience, there is also a heightened focus on accountability and a proven track record of success. Progyny’s innovative program has demonstrated a consistent ability to increase the effectiveness of fertility treatment while lowering the risk of costly complications, including high-risk pregnancies, miscarriages, and multiple births.

“For those employers actively looking for ways to maintain or expand the family building services they are providing to their workforce in 2027, and who recognize the importance of doing so in a fiscally responsible way, Progyny’s standard practice includes an accelerated contracting path when working through one of our many channel partners and our best-in-class implementation timetable,” concluded Anevski.

For Further Information, Please Contact:

Investors:
James Hart
[email protected]

Media:
Alexis Ford
[email protected]

About Progyny

Progyny (Nasdaq: PGNY) is a global leader in women's health and family building solutions, trusted by the nation's leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive and intentionally designed solutions simultaneously benefit employers, patients, and physicians.

Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs.

Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare’s Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times Fastest Growing Companies, INC. 5000, INC. Power Partners and Crain’s Fast 50 for NYC. For more information, visit www.progyny.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release other than statements of historical fact are forward-looking statements, including, without limitation, statements regarding the impact of our sales season and client launches; our anticipated number of clients and covered lives for 2026; our expected utilization rates and mix; the demand for our solutions; our expectations for our selling season for 2027 launches; our positioning to successfully manage economic uncertainty on our business; the timing of client decisions; our ability to retain existing clients and acquire new clients; and our business strategy, plans, goals and expectations concerning our market position, future operations, and other financial and operating information. The words “anticipates,” “assumes,” “believe,” “contemplate,” “continues,” “could,” “estimates,” “expects,” “future,” “intends,” “may,” “plans,” “predict,” “potential,” “project,” “seeks,” “should,” “target,” “will,” and the negative of these or similar expressions and phrases are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions.

Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks include, without limitation, failure to meet our publicly announced guidance or other expectations about our business; competition in the market in which we operate; our history of operating losses and ability to sustain profitability; unfavorable conditions in our industry or the United States economy; our limited operating history and the difficulty in predicting our future results of operations; our ability to attract and retain clients and increase the adoption of services within our client base; the loss of any of our largest client accounts; changes in the technology industry; changes or developments in the health insurance market; negative publicity in the health benefits industry; lags, failures or security breaches in our computer systems or those of our vendors; a significant change in the utilization of our solutions; our ability to offer high-quality support; positive references from our existing clients; our ability to develop and expand our marketing and sales capabilities; the rate of growth of our future revenue; the accuracy of the estimates and assumptions we use to determine the size of target markets; our ability to successfully manage our growth; reductions in employee benefits spending; seasonal fluctuations in our sales; the adoption of new solutions and services by our clients or members; our ability to innovate and develop new offerings; our ability to adapt and respond to the changing medical landscape, regulations, and client needs, requirements or preferences; our ability to maintain and enhance our brand; our ability to attract and retain members of our management team, key employees, or other qualified personnel; risks related to any litigation against us; our ability to maintain our Center of Excellence network of healthcare providers; our strategic relationships with and monitoring of third parties; our ability to maintain our pharmacy distribution network if there is a disruption to our network or its associated supply chains; our relationship with key pharmacy program partners or any decline in rebates provided by them; our ability to maintain our relationships with benefits consultants; exposure to credit risk from our members; risks related to government regulation; risks related to our business with government entities; our ability to protect our intellectual property rights; risks related to acquisitions, strategic investments, or partnerships; federal tax reform and changes to our effective tax rate; the imposition of state and local state taxes; our ability to utilize a portion of our net operating loss or research tax credit carryforwards; our ability to develop or maintain effective internal control over financial reporting; and our ability to adapt and respond to the changing SEC or stakeholder expectations regarding environmental, social and governance practices. For a detailed discussion of these and other risk factors, please refer to our filings with the Securities and Exchange Commission (the “SEC”), including in the section entitled “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and subsequent reports that we file with the SEC, which are available at http://investors.progyny.com and on the SEC’s website at https://www.sec.gov.

Forward-looking statements represent our management’s beliefs and assumptions only as of the date of this press release. Our actual future results could differ materially from what we expect. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons.

Allient Today

$115.48 -1.76 (-1.50%)

As of 09:34 AM Eastern

This is a fair market value price provided by Massive. Learn more.

$42.42▼

$121.420.14%

66.87

$84.00

Allient Inc. NASDAQ: ALNT has long been the kind of company only an engineer would love.

The manufacturer, formerly known as Allied Motion Technologies, makes precision motors, drives, controls, and power-quality equipment that are hidden inside factory robots, surgical tools, military systems, and powersports vehicles.

Get Allient alerts:

Engineers are not its only fans anymore. Allient has become a player in three of the hottest themes in the market today: data center power, defense, and drones.

The challenge for Allient these days is that the stock has run past almost every analyst's price target. For investors, the question is whether the business is changing faster than Wall Street's models, or the stock has gotten ahead of itself.

Earnings Growth Sets a High BarAllient's second-quarter report on Aug. 5 set a high bar for its next earnings release, which is expected in early November. Revenue climbed 10% to $153.8 million, or 9% on an organic, constant-currency basis, topping the $145.7 million analysts expected. The stock jumped about 19% the next trading day.

Profits grew even faster than sales. Gross margin hit a record 34.9%, up 1.7 percentage points, and operating margin rose to 10.2% from 8.4%.

Net income jumped 85% to $10.4 million, or 61 cents per diluted share, versus 34 cents a year earlier. Adjusted earnings came in at 80 cents per share, well ahead of the 61-cent analyst consensus.

That makes the upcoming report an important test of whether the surge in orders, margin improvement, and data center demand carried into the second half of the year.

Record Orders Are the Bigger StoryThe real headline in the report, though, was demand. Orders surged 49% to a record $201.3 million, giving Allient a book-to-bill ratio of 1.31, meaning it booked $1.31 in new business for every dollar it shipped. Backlog swelled to $298 million, most of which management expects to turn into revenue within three to nine months.

The growth is coming from the right places. Industrial sales rose 17%, aerospace and defense rose 16%, and medical rose 9%. The vehicle market fell 7%, however, due to weak powersports demand. Sales tied to data centers and infrastructure reached $16.3 million, or 10.6% of revenue, up 60% from a year earlier.

AI Infrastructure and Defense Are Becoming Bigger Growth EnginesIn short, Allient has repositioned itself in markets that are growing faster than its old ones. In data centers, its Allient Power unit sells harmonic filters and related gear that keep the electricity feeding AI servers clean and stable.

Management says it has the highest-power active filter on the market and is finishing a capacity expansion due online late in the third quarter or early in the fourth.

Defense is the second engine. On Aug. 5, Allient launched a new propulsion controller designed to meet National Defense Authorization Act supply-chain rules for military drones. Then on Sept. 29, the company announced it had earned Cybersecurity Maturity Model Certification Level 2, which is valid for three years and strengthens its ability to compete for defense work involving sensitive information.

For investors who want growth stocks with real profits rather than promises, that’s an appealing mix. Income investors won’t be too impressed, though, even as the board raised the quarterly dividend payout 33% to 4 cents per share in May, a yield of only about 0.14%.

Analyst Targets Haven’t Kept Up With the RallyAllient Stock Forecast Today12-Month Stock Price Forecast:
$84.00
-28.35% Downside

Buy
Based on 6 Analyst Ratings

Current Price$117.24High Forecast$120.00Average Forecast$84.00Low Forecast$70.00Allient Stock Forecast Details

Analysts are clearly supportive. With one Strong Buy rating, four Buy ratings, and a Hold, the consensus rating for Allient is a Buy.

Several analysts, however, have yet to issue new targets for the company, with many still carrying an $80 level set earlier this year, which apparently does not account for a nearly 35% rise in the stock price over the past three months.

Because of that, the 12-month consensus target price remains at $84, about 29% lower than its current trading price.

The most recent adjustment was from JPMorgan Chase NYSE: JPM, which boosted its target two days after recent earnings to $120 per share.

Since the start of the year, Allient shares are up more than 120%.

A Higher Valuation Leaves Less Room for MistakesGiven the unknown duration of the boom that’s occurring in several of its important sectors, valuation is likely the most important risk. At roughly 43 times this year's expected earnings, Allient is priced like a high-growth tech company, not a maker of motors and filters growing sales at high single digits. Any slowdown in orders could hit the shares hard.

There are potentially also some quality-of-earnings questions. Management acknowledged that longer supply-chain lead times are pulling some customer orders forward by about three months, and operating cash flow fell to $20.1 million in the first half from $38.4 million a year earlier, as the company built inventory and waited on receivables.

There is also competition. AMETEK NYSE: AME and Parker-Hannifin NYSE: PH, among others, also fight in this space.

The Next Earnings Report Could Be the Real TestThe reality is that Allient is a more attractive company these days. Margins are at records, debt is falling, orders are piling up, and the company is well-positioned in data centers and defense.

Right now, the company does not appear as a true value stock, and at these levels, investors are paying up for future execution. That puts more weight on Allient's upcoming third-quarter report, when investors will get a fresh look at whether record order activity is translating into revenue, margins are holding near recent highs, and cash flow is beginning to catch up with earnings growth.

If those come in strong, for investors who want to buy stocks with exposure to AI infrastructure and defense spending, Allient provides an appeal that now goes well beyond the world of engineers.

Should You Invest $1,000 in Allient Right Now?Before you consider Allient, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Allient wasn't on the list.

While Allient currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

D-Wave quantum stock sits nearly 40% in the red while one Wall Street analyst holds a price target that would triple your money. The catch is a single quarter that could either validate the bull case or expose a very…

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

D-Wave Quantum (NYSE:QBTS) is trading at $15.79. The consensus price target sits at $34.65, which means about 119% upside.

D-Wave is the only quantum computing company pursuing both annealing and gate-model systems. It runs production workloads for customers such as AT&T (NYSE:T | T Price Prediction) and Optum. In January 2026, it acquired Quantum Circuits to add gate-model capability.

The most bullish call on the stock comes from Rosenblatt Securities analyst John McPeake, who holds the Street-high $43.00 target. That target means about 172% upside from here.

A Revenue Miss and Rising Costs Pushed D-Wave Down Nearly 40% Second-quarter revenue of $3.08M came in 23.63% below the $4.03M consensus and was about flat year over year. GAAP EPS of -$0.13 missed the -$0.0914 estimate.

Operating expenses nearly doubled to $54.98M, and adjusted EBITDA loss grew 85% to $37.1M. Cash and investments fell to $546.2M from $819.3M, with more than 90% of that drop due to the about $250 million cash payment for Quantum Circuits. Share count grew from 266.6M to 358.7M during fiscal 2025.

The stock is down 39.62% year to date and 66% below its 52-week high of $46.75. Other quantum stocks fell too, but D-Wave has the worst year-to-date loss in the group.

Rosenblatt’s $43 Call Rests on Annealing Already Earning Revenue Of the 17 analysts tracked, 1 rates it Strong Buy, 15 rate it Buy and 1 rates it Hold. None rate it Sell. Rosenblatt reiterated its Buy rating despite the miss.

Rosenblatt’s view: D-Wave leads in commercial annealing systems that solve optimization problems today. Leap should generate high-margin recurring cloud revenue as customers move from pilot programs into production. Hybrid quantum-classical solvers deliver value now, so customers don’t wait for fault-tolerant machines.

First-half bookings reached $35.5M versus $2.9M a year earlier. Remaining performance obligations rose 668% to $40.7M, with about 57% recognized within 12 months. D-Wave has six customer applications in production.

Management expects third-quarter revenue to be “up modestly” and fourth-quarter revenue to be “up significantly,” with two annealing systems likely shipping in the fourth quarter. D-Wave doesn’t expect significant gate-model cloud revenue until 2032. Price targets are not guarantees, and this one depends on annealing doing the heavy work for years.

Quantum Stocks Fell Together, and D-Wave Fell Hardest Every stock in the peer group sold off. D-Wave’s decline was sharper than its peers’.

IonQ (NYSE:IONQ) is down 3.52% year to date at $43.33. Its average target of $66.63 means about 54% upside. Analysts rate it 1 Strong Buy, 11 Buy, 2 Hold.

Rigetti Computing (NASDAQ:RGTI) is down 31.51% year to date at $15.17. Its target of $28.52 means about 88% upside. Ratings: 1 Strong Buy, 8 Buy, 4 Hold.

Quantum Computing Inc. (NASDAQ:QUBT) is down 23.39% year to date at $7.86. Its target of $18.67 means about 138% upside. Six analysts cover it (4 Buy, 2 Hold).

Quantum Computing Inc. has the largest consensus upside on paper. D-Wave ranks second and has the widest and most bullish analyst coverage in the group.

D-Wave Is Down 39% While the S&P 500 Rises D-Wave trades at $15.79, less than halfway to its $34.65 consensus target. The stock is down 39.62% year to date, while the S&P 500 is up 14.25%.

Shares have fallen 4.76% over the past month and trade below the 50-day average of $18.14 and 200-day average of $20.80. On trailing revenue of $12.425M, the stock trades at a price-to-sales ratio of 481.83.

D-Wave’s Fourth-Quarter Deliveries Will Test the 172% Call The case for the stock gets stronger if both annealing systems ship in the fourth quarter, the backlog turns into revenue on schedule and Leap’s production customers like Optum and AT&T expand their work. That path could close much of the gap to the consensus target.

The bear case gains weight if fourth-quarter deliveries slip into 2027, spending keeps outpacing revenue and D-Wave issues more shares to fund a gate-model program that won’t produce significant revenue until 2032. In that case, today’s low price would be a value trap.

The production customers and backlog are real, and analysts are almost unanimously positive. The fourth quarter has to deliver before Rosenblatt’s $43.00 target looks realistic.

Contact [email protected] for any questions or corrections.

Toronto Dominion Bank (The) (NYSE:TD – Get Free Report) (TSE:TD) announced a quarterly dividend on Thursday, August 27th. Shareholders of record on Friday, October 9th will be given a dividend of C$1.12 per share by the bank on Saturday, October 31st. This represents a $4.48 annualized dividend and a yield of 3.8%. The ex-dividend date is Friday, October 9th.

Toronto Dominion Bank has increased its dividend payment by an average of 0.1%annually over the last three years and has increased its dividend annually for the last 12 consecutive years. Toronto Dominion Bank has a payout ratio of 52.1% meaning its dividend is sufficiently covered by earnings. Analysts expect Toronto Dominion Bank to earn $7.67 per share next year, which means the company should continue to be able to cover its $3.23 annual dividend with an expected future payout ratio of 42.1%.

Toronto Dominion Bank Stock Up 1.0% TD opened at $118.22 on Wednesday. The company has a market cap of $194.45 billion, a P/E ratio of 17.57, a P/E/G ratio of 1.16 and a beta of 0.75. The business’s 50-day moving average price is $120.42 and its 200-day moving average price is $113.90. The company has a current ratio of 1.03, a quick ratio of 1.03 and a debt-to-equity ratio of 0.09. Toronto Dominion Bank has a 12 month low of $77.95 and a 12 month high of $125.46.

Toronto Dominion Bank (NYSE:TD – Get Free Report) (TSE:TD) last issued its earnings results on Thursday, August 27th. The bank reported $1.98 earnings per share for the quarter, beating the consensus estimate of $1.74 by $0.24. Toronto Dominion Bank had a return on equity of 14.88% and a net margin of 14.41%.The company had revenue of $12.07 billion during the quarter, compared to analysts’ expectations of $10.70 billion. During the same period in the prior year, the business posted $2.20 EPS. Toronto Dominion Bank’s quarterly revenue was up 6.9% compared to the same quarter last year. On average, equities analysts expect that Toronto Dominion Bank will post 7.04 EPS for the current year. Institutional Trading of Toronto Dominion Bank A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Cornerstone Financial Management LLC raised its holdings in Toronto Dominion Bank by 77.2% in the 2nd quarter. Cornerstone Financial Management LLC now owns 218 shares of the bank’s stock worth $26,000 after purchasing an additional 95 shares in the last quarter. Bayban purchased a new position in shares of Toronto Dominion Bank during the fourth quarter valued at about $28,000. Brown Lisle Cummings Inc. increased its position in shares of Toronto Dominion Bank by 88.4% during the first quarter. Brown Lisle Cummings Inc. now owns 407 shares of the bank’s stock valued at $38,000 after buying an additional 191 shares during the period. Continuum Advisory LLC bought a new position in Toronto Dominion Bank in the second quarter worth about $43,000. Finally, NBH Bank purchased a new stake in Toronto Dominion Bank in the second quarter worth about $73,000. Hedge funds and other institutional investors own 52.37% of the company’s stock.

Toronto Dominion Bank Company Profile (Get Free Report)

Toronto-Dominion Bank, operating as TD Bank Group, is a Canadian financial services company headquartered in Toronto, Ontario. The bank was formed in 1955 through the merger of The Bank of Toronto and The Dominion Bank and serves customers in Canada and the United States.

TD provides a broad range of banking and financial services, including personal and commercial deposit accounts, lending, mortgages, credit cards, payments, investment products and financial advice. Its Canadian operations serve individuals, businesses and institutions, while its U.S.

Further Reading Five stocks we like better than Toronto Dominion Bank Constellation Energy’s Google Deal Shows Why Nuclear Uprates Matter for AI Lamb Weston’s Turnaround Is Starting to Look Real These 3 Stocks Got the Most Love From Analysts in September Record French Debt Could Create Opportunities for U.S. Market Operators

Receive News & Ratings for Toronto Dominion Bank Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Toronto Dominion Bank and related companies with MarketBeat.com's FREE daily email newsletter.

Automobilka Porsche představila novou strategii, která počítá s výrazným snižováním nákladů a větším důrazem na nejluxusnější modely. Německý výrobce sportovních vozů chce v budoucnu prodávat méně aut, ale za vyšší ceny, a zajistit si tak vysokou ziskovost i v době, kdy evropský automobilový průmysl čelí rostoucím nákladům, čínské konkurenci a americkým clům.

Německý výrobce luxusních sportovních vozů Porsche plánuje v příštích letech výrazně snížit náklady. Firma v dnešní tiskové zprávě o nové strategii rovněž uvedla, že hodlá klást menší důraz na objem prodeje a že se zaměří na nabídku automobilů nejvyšší třídy. Chce tak v budoucnosti prodávat méně vozů, ale za vyšší ceny, napsala agentura AFP.

"Naše strategie položí základy ke zvýšení efektivity, produktivity a ziskovosti Porsche," uvedl šéf podniku Michael Leiters. "Nyní se soustředíme zejména na snižování nákladů a posílení finanční pozice podniku," dodal.

Automobilka Porsche chce v rámci nové strategie zajistit, aby dosahovala ziskovosti i při objemu prodeje pod 200.000 vozů ročně. V loňském roce přitom dodala zákazníkům 279.449 vozů.

Německý automobilový průmysl se v poslední době potýká s řadou problémů, včetně vysokých nákladů, nadbytečných kapacit, rostoucí čínské konkurence nebo amerických cel.

Automobilka Porsche v roce 2022 vstoupila na frankfurtskou akciovou burzu. Jejím většinovým vlastníkem nicméně zůstal německý automobilový koncern Volkswagen, jehož součástí je také Škoda Auto.

Dozorčí rada koncernu Volkswagen minulý měsíc schválila největší restrukturalizační plán v historii podniku, který zahrnuje rozsáhlé rušení pracovních míst a omezení počtu modelů. Škoda Auto opakovaně uvedla, že nový transformační plán koncernu nemá na její aktivity žádný přímý dopad.

Automobilka Porsche byla dlouhou dobu spolehlivým zdrojem zisků koncernu Volkswagen. V současnosti je však podle analytiků pro koncern spíše přítěží a dostává se do stínu Škody Auto. "Česká značka se fakticky stává novým Porsche celé skupiny," uvedl minulý měsíc nezávislý analytik automobilového průmyslu Matthias Schmidt.

For most of its history, Space Exploration Technologies (SPCX +0.48%) was synonymous with rockets. That description is starting to look outdated. Following its initial public offering (IPO) in June, SpaceX gives investors exposure to several markets at once: commercial space launches, government contracts, Starlink, artificial intelligence (AI) infrastructure, and perhaps even space-based computing.

With SpaceX expected to report its next quarterly earnings in early November, investors have a decision to make: Is October a good time to buy SpaceX stock, or has excitement surrounding the company gotten ahead of itself?

Image source: The Motley Fool.

AI is becoming a meaningful contributor for SpaceX SpaceX's expansion into AI infrastructure might be the most underappreciated part of the story. Around the time of its IPO, the company signed compute agreements with Anthropic and Google. Since its public debut, SpaceX has expanded its AI customer list.

Reflection AI is spending roughly $150 million per month to rent a cluster of Nvidia GB300 chips at SpaceX's Colossus 2 data center. The deal value could be worth up to $6.3 billion over the entire life of the contract. During SpaceX's Q2 earnings call, management disclosed the company signed a six-month cloud services agreement worth $6.7 billion and noted that capacity will ramp throughout October. Most recently, SpaceX CFO Bret Johnsen shared with investors another hosting agreement worth approximately $1.11 billion per month, or $13.3 billion annually.

Taken together, SpaceX is forecasting its combined businesses could reach a $100 billion annualized revenue run rate by December. This is important because this growth underscores how the company is diversifying beyond its roots in launch services. SpaceX is proving it can build AI infrastructure at hyperscale speed, sell compute capacity to some of the world's fastest-growing technology companies, operate a high-margin connectivity provider in Starlink, and potentially use its own rockets to launch computing infrastructure into orbit.

Today's Change

(

0.48

%) $

0.83

Current Price

$

171.92

A trifecta of launch milestones The last several days were a good showcase of SpaceX's other competitive advantage: launch cadence. On Sept. 28, Starship reached orbit for the first time and successfully deployed 26 Starlink V3 satellites. Although the mission ended earlier than originally planned following an engine issue, successfully putting an operational payload into orbit represents an unprecedented step toward making Starship commercially useful.

A trifecta of launch sequences subsequently occurred on Oct. 1. SpaceX launched Crew-13 to the International Space Station (ISS) for NASA, further validating Falcon 9 and Dragon as capable human-spaceflight infrastructure.

A few hours later, the company carried 130 payloads into orbit as part of the Transporter-18 mission. Of note, one was Google's prototype satellite for Project Suncatcher, an experiment testing whether its custom silicon, called Tensor Processing Units (TPUs), could support AI computing in space. This mission is particularly interesting given Google's existing relationship with SpaceX on terrestrial AI compute.

Finally, SpaceX's Falcon Heavy was part of a classified launch, called NROL-97. Participating in a mission for the National Reconnaissance Office mission expands SpaceX's role beyond commercial deployments into national security launches.

Should you buy SpaceX stock before earnings? I'll admit that SpaceX's business looks stronger now than it did a few months ago. But that doesn't automatically make SpaceX stock a screaming buy in October. The company is already valued at roughly $2 trillion, meaning investors aren't exactly discovering a new growth story. Moreover, SpaceX still carries hefty losses as it invests aggressively in AI infrastructure and Starship.

With earnings just a few weeks away, SpaceX really needs to demonstrate that its compute contracts are translating into revenue and improving economics -- not merely generating buzzy headlines. With this in mind, I wouldn't view October as a month to chase SpaceX's momentum simply because Starship reached orbit or several launches went well.

For long-term investors, the bigger thesis remains compelling. SpaceX increasingly sits at the intersection of AI, satellite internet, government infrastructure, and commercial spaceflight. Investors who want exposure to the company are best off using dollar-cost averaging --building a position gradually at different price points over time rather than making earnings day an all-or-nothing bet.

Meta's Muse personal agent has been topping app store charts. Now, the "centerpiece" of the company's artificial intelligence strategy, as CEO Mark Zuckerberg describes it, needs to become something people make a habit of using.

The buzz around Meta's AI agent has excited investors. The stock is up about 20% since the app's launch a month ago and recorded its best month in September since 2022.

While Meta is still currently the top free app on Apple's iOS store, the bigger challenge for the Facebook parent is to get people to keep using Muse after the magic wears off. Meta needs its personal agent to be an anchor app for the company, which has been trailing competitors like OpenAI and Google in the red-hot AI market.

"Muse has an opportunity to be sticky with consumers because it's a task-completer, rather than just a chatbot," Meredith Whalen, chief research officer at IDC, said in an email.

Whalen said consumers are using current AI tools for a range of tasks, but it's unclear if they'll be willing to hand over the kind of personal data required to create an efficient digital assistant. That's a particularly big obstacle for Meta, which just agreed to an almost $17 billion settlement with a group of states that alleged the company misrepresented the extent of child mental health harms caused by apps like Facebook and Instagram.

"The real question is trust," Whalen said.

Meta is pitching Muse to both consumers and small businesses for tasks like organizing personal emails, searching for shopping deals or seeking out prospective customers. Although Meta lets users access Muse for free, it also sells monthly subscription plans for $20 or $100, depending on tokens, a metric the company uses to calculate the power AI agents need to accomplish tasks.

In offering Muse for free out of the gate, the company can get an understanding of how and why people are using it, said Whalen, who noted that, "Price comes later, once the habit is established."

watch now

Coders have found AI agents helpful as software engineering tools, but the general public and even business leaders are still grappling with the potential for supercharged digital assistants, beyond acting as mere question-and-answering services.

"I would say that widely, enterprise-scale AI agent adoption is still page one, chapter one," said Ketan Karkhanis, CEO of ThoughtSpot, which sells AI agent technologies to businesses.

Consumers are just getting started with AI agents.

Karkhanis said he hasn't seen the kinds of "killer use cases" that would make apps like Muse more compelling than merely being a "next-gen Alexa" or Siri voice assistant that people might use to tell them the weather.

Andrew Geller, executive producer of 1stAveMachine, said his media firm develops its own internal agentic tools for certain production tasks. He views Muse and other consumer-focused AI agents as being "quite helpful" in introducing the technology to the masses, but says they're hardly life-changing.

Geller said he was "early on the OpenClaw train," referring to the so-called open-source harness for managing AI agents that took off earlier this year. He said he discovered that personal use of AI agents can be fun, but also "kind of a little banal," particularly when contrasted with the more heavy-duty uses related to coding.

Bring on the Personal AI assistantsA number of other tech firms are trying to commercialize AI agents for the masses by first enticing users to join for free.

Former Yahoo CEO Marissa Mayer is taking a try-before-you-buy approach with her new photo-centric AI agent startup Dazzle, a tactic she said is important "for those occasional users or those users who are just trying to see what the service can do at the very beginning."

Dazzle analyzes users' personal photos to understand aspects of their lives, such as their family members or interests, and then can take actions like reminding someone that a pair of shoes they recently looked up is on sale online.

It's a strategy she learned from her early tenure at Google, before the company built its market-leading online ad platform.

"What we're really trying to do is see what use cases are really popping with users, what do they see as really helpful, and that will guide it," Mayer said about Dazzle's first week post-launch.

Mayer compared the pricing and adoption approach to Uber's evolution. The ride-hailing company began with black town cars before introducing lower-priced options for a wider swath of users.

"It's a luxury to be able to have these wonderful recommendations and to have this level of convenience," Mayer said.

Dazzle is considering transaction fees and subscriptions.

"We want to be running a service where people feel that they're getting value on a relatively continuous basis over time," Mayer said.

At Wajo AI, CEO Shivani Poddar is also contemplating business models for her new AI-powered digital assistant startup, which lets people research and book appointments or order gifts for family members.

Poddar, who has previously built voice-assistant technologies for Amazon Alexa and at Facebook, is letting people access the service for free for now. While Poddar believes businesses may be willing to pay subscription fees, she's not yet convinced that "the everyday person" will want to sign up, and instead may be more willing to pay service fees based on outcomes, like how Airbnb makes money from bookings.

The stakes are highest for Meta, which went on a massive spending spree last year to acquire talent and build a business in AI that could compete with OpenAI and Anthropic. Zuckerberg is desperate to diversify away from online ads, which still account for almost all of the company's revenue, and he's got a long way to go to prove that Muse can be a key piece of that effort.

Zuckerberg, at least to an extent, has time on his side.

"Whoever can subsidize users and wait has the advantage," IDC's Whalen said. "And Meta's ad business can pay for a lot of waiting."

WATCH: Meta hits the mark.

watch now

AMD has surged past every analyst price target on the back of gigawatt-scale AI chip commitments, but the product that justifies this valuation has not yet shipped a single unit at scale.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

AMD (NASDAQ:AMD | AMD Price Prediction) trades at $649.42. The stock is up 203.24% year to date and now trades above the average Wall Street price target. That leaves investors considering record growth against a very demanding multiple.

AMD designs CPUs and GPUs. It competes with NVIDIA (NASDAQ:NVDA) in AI accelerators and with Intel (NASDAQ:INTC) in server processors. Last quarter, revenue rose 50.11% to $11.54 billion, beating the $11.31 billion estimate. Data Center revenue climbed 107% and now makes up 58% of sales.

Gigawatt Deals Could Make Today’s Multiple Look Cheap Bulls look past trailing earnings. AMD trades at a forward P/E of about 40, and its PEG ratio of 0.626 is below 1, which suggests growth is exceeding price. The 2027 EPS consensus has increased to $15.5833 from $13.1770 90 days ago.

The customer list is strong. OpenAI has committed to 6 gigawatts of AMD GPUs, Meta Platforms (NASDAQ:META) to up to 6 GW, and Anthropic to up to 2 GW of MI450 chips in Helios racks. Management says Helios demand is “tracking ahead of our initial forecasts” and expects Data Center revenue to “more than double year-over-year in 2027.”

A Triple-Digit Trailing Multiple Leaves No Room for a Helios Stumble Bears point to a trailing P/E of about 161, a price-to-free-cash-flow ratio of 158 and a free cash flow yield of just 0.63%. Free cash flow fell 9.89% last quarter as capital spending jumped 186.52%.

Gaming revenue dropped 31%, and export controls cost about $440 million in fiscal 2025. Helios is complex, and management expects yields to improve only over the first few quarters of the ramp. With a beta of 2.454, any delay would hit a stock already priced for perfect execution.

Helios Shipments Will Decide Which Side Wins AMD guided third-quarter revenue to about $13 billion, with a non-GAAP gross margin near 56%. Helios starts contributing at the end of the third quarter, with a more substantial ramp in the fourth quarter. Anthropic’s first gigawatt begins in the first half of 2027.

Strong Helios revenue and increased 2027 estimates would support the optimistic thesis. Yield problems or customer delays tied to power and land preparation would support the pessimistic thesis. (We reverse-engineered what the biggest tech winners looked like early in a free report you can grab here.)

Shares Have Run Past the Average Analyst Target At $649.42, AMD sits above the consensus target of $629.21, which implies 3.1% downside. Price targets are only one data point, and these have trailed the rally. Of 55 analysts:

Strong Buy: 5 Buy: 39 Hold: 11 Sell: 0 AMD is up 218.8% over the past year, compared with 16.01% for the S&P 500. Over the past month it rose 35.98%, and the index added 1.16%. The stock trades near its 52-week high of $658.52 and well above its 50-day average of $513.53.

Helios Must Prove Itself Before AMD’s Multiple Makes Sense At $649.42, AMD trades on expectations that Helios still has to confirm.

Operations are running smoothly. The share price, however, already reflects about 42 times 2027 consensus EPS, so much of the expected growth is priced in. The optimistic thesis needs fourth-quarter Helios revenue to arrive on schedule and 2027 estimates to keep increased. The pessimistic scenario would need yield setbacks, slipping deployments, or free cash flow that keeps falling as capital spending grows.

Timing matters here. The stock sits above its consensus target after a one-month surge. A decline is possible if the next earnings report only matches guidance. The gigawatt-scale order pipeline, however, is still growing.

Over the next two quarters, keep an eye on Data Center growth, gross margin holding near 56%, Helios customer diversity, and capital spending versus free cash flow. AMD’s growth is real, and at this price the valuation depends on Helios showing up in the numbers.

Contact [email protected] for any questions or corrections.

One of the most anticipated initial public offerings (IPOs) of 2026 could be coming shortly: Anthropic. Anthropic is an artificial intelligence (AI) lab that makes the Claude family of large language models. Anthropic has emerged as one of the leading companies in this area, and the market has been clamoring for it to go public for a while. Some estimates value the IPO at as much as $2 trillion, which is a very expensive price tag for how much the company generates and how much money it's losing. However, there will still be a large chunk of investors who buy in at the IPO. This may cause a short-term rally, but after that, the stock may need to show some profitability improvements to be considered a great long-term pick.

However, one statement in the leaked Anthropic prospectus drives me to conclude that investors should be buying up stocks of computing unit suppliers. The leader in this segment is Nvidia (NVDA +0.14%), and it looks like it could be a great stock to buy now based on these comments from Anthropic.

Image source: Getty Images.

AI could be much more advanced than it is now One of the most incredible statements from Anthropic in its prospectus document, according to Reuters, is that AI is "limited principally by the availability of compute." That's an incredible statement, as it basically says that if we had more computing power, we could be more advanced.

One of the primary reasons for Anthropic to go public is so it can have access to more funding sources, as it can raise money through debt issuance as well as by issuing more shares in the market. Anthropic isn't being shy about how much it's planning to spend, either: $518 billion during the next decade. That's a huge amount of growth ahead, and it could even be underestimating that if more compute becomes available.

Anthropic tells prospective investors that it doesn't believe demand will be an issue, just computing supply. That bodes well for companies like Nvidia, as it's supplying a large chunk of the computing power to the AI industry.

Nvidia's investment thesis hinges on supply constraints Computing unit suppliers like Nvidia still cannot make enough hardware to satisfy the demand from AI hyperscalers. In fact, Nvidia's forecast for growth of 70% during the next fiscal year hinges on the industry remaining supply-constrained. However, Anthropic believes this condition will persist for some time, continuing to drive AI hyperscalers to pay sky-high prices for computing units.

Premium Feature

Moneyball Superscore

95/100

Today's Change

(

0.14

%) $

0.34

Current Price

$

239.24

This benefits Nvidia and its peers, and as I think about the consequences of a company like Anthropic going public, it pushes me to invest in Nvidia and other computing unit suppliers rather than Anthropic. Anthropic has a lot to prove with its business model, as it must build a huge subscription base that uses its products. It's likely, but it requires an enormous audience for the finances to make sense.

Let's say 1 billion people pay a $50 monthly subscription for Anthropic's product. That will generate $600 billion in revenue per year. That's an extremely bullish projection and a huge amount of money, but consider this: Wall Street analysts expect Nvidia to generate nearly $700 billion in 2028.

What does this mean? I think it's pretty simple. Nvidia is the world's most value company. It took it more than three decades to reach that point and it has prospered in recent years amid enormous AI spending. Anthropic has a long way to go before it's a viable business, much less a company on par with Nvidia -- and there's a lot of risk ahead.

This makes Nvidia an excellent long-term investment, as companies like Anthropic will fuel its growth. As a result, I'm more interested in buying Nvidia than I am in Anthropic.

Walt Disney (DIS +0.41%) has historically been known as a leader in cable TV, thanks to popular networks like ABC and ESPN. In recent years, the company's streaming operations have gotten a lot of attention, thanks to the success of Disney+ and Hulu, as well as the launch of the stand-alone ESPN platform.

These are important to Walt Disney, to be sure. However, investors should understand that these parts of the business pale in comparison to the entertainment stock's most lucrative segment.

Image source: The Motley Fool.

During third-quarter 2026 (ended June 27), Disney's experiences segment posted 10% year-over-year revenue growth. This was a better gain than any other segment. Its sales figure of $10 billion accounted for 40% of the entire company's total.

Operating income for experiences soared 20%. This profit metric represented 54% of the company's total operating income.

Premium Feature

Moneyball Superscore

75/100

Today's Change

(

0.41

%) $

0.42

Current Price

$

104.03

The experiences segment includes the theme parks and cruises. These make up what is arguably the most competitively advantaged segment of the business. They have high barriers to entry, and because Disney owns an immense portfolio of intellectual property, these experiences are differentiated in the industry. Consequently, they have historically had pricing power.

Despite the scale of this division, there is still a sizable growth runway to capture. In September 2023, the management team announced a 10-year, $60 billion capital investment plan to bolster the experiences segment in an effort to reach more people around the world. This can support the overall company's long-term financial performance.

Neil Patel has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Walt Disney. The Motley Fool has a disclosure policy.

PepsiCo, Inc. (NASDAQ:PEP) will release third-quarter earnings before the opening bell on Thursday, Oct. 8.

With the recent buzz around PepsiCo, some investors may be eyeing potential gains from the soft drink company’s dividends too. As of now, PepsiCo has an annual dividend yield of 4.71%, based on a quarterly dividend of $1.48 per share ($5.92 a year).

So, how can investors exploit its dividend yield to pocket a regular $500 monthly?

To earn $500 per month, or $6,000 annually, from dividends alone, you would need an investment of about $127,470, or around 1,014 shares. For a more modest $100 per month or $1,200 per year, you would need $25,519 or around 203 shares.

To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($5.92 in this case). So, $6,000 / $5.92 = 1,014 ($500 per month), and $1,200 / $5.92 = 203 shares ($100 per month).

Note that dividend yield can change on a rolling basis, as dividend payments and stock prices both fluctuate over time.

How that works: The dividend yield is computed by dividing the annual dividend payment by the stock’s current price.

For example, if a stock pays an annual dividend of $2 and trades at $50, the dividend yield is 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).

Similarly, changes in dividend payments can affect yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, the yield will also decrease.

Price ActionPepsiCo shares rose 0.1% to close at $125.71 on Tuesday.

Analysts expect the company to report quarterly earnings of $2.30 per share, up from $2.29 per share a year ago. The consensus estimate for PEP’s quarterly revenue is $24.96 billion. It reported $23.94 billion last year, according to Benzinga Pro.

Ahead of quarterly earnings, RBC Capital analyst Nik Modi, on Tuesday, maintained PepsiCo with a Sector Perform and lowered the price target from $161 to $150.

Photo via Shutterstock

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Pfizer Inc. (NYSE:PFE – Get Free Report) declared a quarterly dividend on Tuesday, October 6th. Stockholders of record on Friday, November 6th will be paid a dividend of $0.43 per share by the biopharmaceutical company on Monday, December 7th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.3%. The ex-dividend date of this dividend is Friday, November 6th.

Pfizer has decreased its dividend payment by an average of 0.1%annually over the last three years and has increased its dividend every year for the last 16 years. Pfizer has a payout ratio of 55.8% meaning its dividend is sufficiently covered by earnings. Research analysts expect Pfizer to earn $2.95 per share next year, which means the company should continue to be able to cover its $1.72 annual dividend with an expected future payout ratio of 58.3%.

Pfizer Stock Performance Shares of PFE stock opened at $27.48 on Wednesday. The company has a market capitalization of $156.63 billion, a price-to-earnings ratio of 36.16, a P/E/G ratio of 1.84 and a beta of 0.32. Pfizer has a 1-year low of $23.62 and a 1-year high of $29.21. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71. The stock’s fifty day simple moving average is $27.50 and its 200-day simple moving average is $26.48.

Pfizer (NYSE:PFE – Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The firm had revenue of $15.03 billion during the quarter, compared to the consensus estimate of $14.40 billion. During the same period in the prior year, the business earned $0.78 EPS. The business’s revenue for the quarter was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, sell-side analysts predict that Pfizer will post 2.98 earnings per share for the current fiscal year. Hedge Funds Weigh In On Pfizer Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Moody National Bank Trust Division lifted its stake in Pfizer by 3.7% in the third quarter. Moody National Bank Trust Division now owns 86,627 shares of the biopharmaceutical company’s stock valued at $2,471,000 after acquiring an additional 3,061 shares during the last quarter. Legacy Private Trust Co. acquired a new position in shares of Pfizer during the 3rd quarter worth $207,000. Park National Corp OH raised its holdings in shares of Pfizer by 6.4% during the 3rd quarter. Park National Corp OH now owns 257,556 shares of the biopharmaceutical company’s stock valued at $7,345,000 after purchasing an additional 15,475 shares in the last quarter. Baker Tilly Wealth Management LLC lifted its stake in shares of Pfizer by 35.0% in the 3rd quarter. Baker Tilly Wealth Management LLC now owns 12,951 shares of the biopharmaceutical company’s stock valued at $369,000 after purchasing an additional 3,361 shares during the last quarter. Finally, Argent Capital Management LLC acquired a new stake in shares of Pfizer in the 3rd quarter valued at $8,128,000. Institutional investors own 68.36% of the company’s stock.

About Pfizer (Get Free Report)

Pfizer Inc (NYSE:PFE) is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research and commercial activities focus on areas including oncology, inflammation and immunology, internal medicine, hospital care and vaccines.

The company’s portfolio includes widely used products such as the Prevnar family of pneumococcal vaccines, Ibrance for certain breast cancers, Eliquis for preventing blood clots, Xeljanz for inflammatory conditions, and Vyndaqel for transthyretin amyloidosis.

See Also Five stocks we like better than Pfizer Allient’s Data Center and Defense Momentum Is Raising the Stakes Constellation Energy’s Google Deal Shows Why Nuclear Uprates Matter for AI Lamb Weston’s Turnaround Is Starting to Look Real These 3 Stocks Got the Most Love From Analysts in September

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

MetLife, Inc. (NYSE:MET – Get Free Report) announced a quarterly dividend on Tuesday, October 6th. Shareholders of record on Tuesday, November 3rd will be paid a dividend of $0.5925 per share by the financial services provider on Tuesday, December 8th. This represents a $2.37 annualized dividend and a yield of 2.4%. The ex-dividend date of this dividend is Tuesday, November 3rd.

MetLife has increased its dividend by an average of 0.0%annually over the last three years and has raised its dividend annually for the last 12 consecutive years. MetLife has a payout ratio of 22.9% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect MetLife to earn $10.70 per share next year, which means the company should continue to be able to cover its $2.37 annual dividend with an expected future payout ratio of 22.1%.

MetLife Stock Performance Shares of MET stock opened at $97.22 on Wednesday. The company has a market capitalization of $62.56 billion, a P/E ratio of 18.63, a price-to-earnings-growth ratio of 0.92 and a beta of 0.78. MetLife has a 52 week low of $67.33 and a 52 week high of $100.93. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.20 and a current ratio of 0.20. The company’s 50 day moving average price is $96.53 and its two-hundred day moving average price is $87.17.

MetLife (NYSE:MET – Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The financial services provider reported $2.43 EPS for the quarter, topping analysts’ consensus estimates of $2.30 by $0.13. MetLife had a net margin of 4.57% and a return on equity of 23.39%. The business had revenue of $13.52 billion for the quarter, compared to analyst estimates of $19.67 billion. During the same period last year, the business posted $2.02 earnings per share. The firm’s quarterly revenue was up 10.5% on a year-over-year basis. On average, analysts expect that MetLife will post 9.85 earnings per share for the current fiscal year. Analysts Set New Price Targets A number of research firms recently issued reports on MET. Mizuho increased their price objective on MetLife from $95.00 to $102.00 and gave the stock an “outperform” rating in a report on Thursday, July 9th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of MetLife in a research note on Friday, September 11th. Wells Fargo & Company boosted their price objective on shares of MetLife from $101.00 to $109.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 19th. TD Cowen increased their target price on shares of MetLife from $105.00 to $110.00 and gave the stock a “buy” rating in a report on Monday. Finally, Morgan Stanley lifted their price target on shares of MetLife from $103.00 to $111.00 and gave the company an “overweight” rating in a research note on Monday, August 24th. Twelve investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $105.08.

View Our Latest Report on MET

About MetLife (Get Free Report)

MetLife, Inc is a global financial services company that provides insurance, employee benefits and retirement solutions. Its products and services include life insurance, dental and vision coverage, disability insurance, accident and health benefits, annuities, and savings and retirement products.

The company serves individuals, employers and institutions through group benefits, workplace solutions and individual insurance offerings. MetLife also provides investment and retirement services designed to help employers and employees prepare for long-term financial needs.

Founded in 1868, MetLife is headquartered in New York City and operates through businesses in the United States and international markets, including regions across Latin America, Asia and Europe.

See Also Five stocks we like better than MetLife Allient’s Data Center and Defense Momentum Is Raising the Stakes Constellation Energy’s Google Deal Shows Why Nuclear Uprates Matter for AI Lamb Weston’s Turnaround Is Starting to Look Real These 3 Stocks Got the Most Love From Analysts in September

Receive News & Ratings for MetLife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetLife and related companies with MarketBeat.com's FREE daily email newsletter.

Realty Income earned one of investing's most coveted quality stamps, yet buyers who celebrated the news found themselves holding a stock that went nowhere for years. The milestones that felt like validation turned out to be traps, and the pattern…

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Realty Income (NYSE:O) built its reputation on reliable monthly income. (Seven of our favorite monthly payers are rounded up in this free report.) Among the key milestones discussed here, its first two were excellent entry points; the three that followed were poor ones. Each return below runs from the milestone’s adjusted price to the October 6, 2026, close of $54.25, adjusted for splits and dividends.

A 2013 Buyer Got In Before the Crowd Realty Income closed its American Realty Capital Trust acquisition on January 22, 2013, before it became a household name in the income-investing world. This entry sets the baseline.

Adjusted entry price: $22.20 $1,000 is now worth: $2,443.80 Total return: 144.38% S&P 500 Admission Still Paid Off S&P Dow Jones Indices announced in March of 2015 that Realty Income would replace Windstream Holdings in the S&P 500, effective after the close on April 6, 2015. This entry was strong, though lower than the 2013 one.

Adjusted entry price: $28.50 $1,000 is now worth: $1,903.70 Total return: 90.37% Six Years as a Dividend Aristocrat With Nothing to Show Realty Income announced on January 31, 2020, that it would join the S&P 500 Dividend Aristocrats index on February 3, 2020. The index held 64 components, with Realty Income one of only three real estate investment trusts (REITs) included. Income investors treat that recognition as a quality stamp.

A buyer that day is essentially flat after more than six years with dividends included. For a stock whose case rests on reliable income, a total return near zero means share price decline has offset the dividend stream.

Adjusted entry price: $54.21 $1,000 is now worth: $1,000.70 Total return: 0.07% VEREIT Buyers Got a Spin-Off and Little Else Per PR Newswire, Realty Income closed its VEREIT merger on November 1, 2021, and completed the Orion Office REIT (NYSE:ONL) spin-off and shares began trading on November 15, 2021, so buyers received Orion shares soon after.

Adjusted entry price: $53.15 $1,000 is now worth: $1,020.60 Total return: 2.06% Spirit Deal Buyers Arrived After the Damage Realty Income acquired Spirit Realty Capital on January 23, 2024, after shares had already fallen. That lower starting point made it the best of the three recent entries.

Adjusted entry price: $48.11 $1,000 is now worth: $1,127.60 Total return: 12.76% A Fresh Selloff Weighs on Every Window Measured against a premarket reading of $54.38 on October 7, 2026, trailing performance was:

One week: down 0.89% One month: down 10.77% Year to date: 0.35% One year: down 4.22% Five years: 7.25% Ten years: 47.19% The one-month decline means every milestone return above is measured to a low price.

Recognition Arrived After the Easy Money The milestones that felt like validation were the worst times to buy Realty Income. The entries that worked came either years before recognition or after a selloff had reset the price. Prestige confirmed what the stock had already done; buyers who paid for it were left with dividends and little else.

Contact [email protected] for any questions or corrections.

Helping researchers to move from discovery to breakthrough up to 8x faster by combining AI, automation and innovation from across Danaher's ecosystem of industry-leading technologies

, /PRNewswire/ -- Danaher Corporation (NYSE: DHR) today announced plans to launch its first AI-powered autonomous lab, designed to help researchers develop custom antibodies and other molecular tools faster and more efficiently. Expected to operate at scale in early 2027, the lab will combine artificial intelligence, robotics and technologies from several Danaher operating companies in one connected workflow. It is the first step in a broader Danaher initiative to create smart instruments, integrated workflows and autonomous labs that accelerate scientific research.

Danaher's first AI-powered autonomous lab is designed to deliver:

Speed: Up to 8x faster discovery of affinity reagents, helping researchers get from idea to breakthrough sooner Scale: Unlocking up to a tenfold increase in annual reagent generation, from tens to hundreds of reagents per year as the lab scales Quality: Each design built in the lab would also be verified, tested and fed back to improve the next, without trading speed for scientific rigor Sustainability: Over time, this approach is expected to complement traditional immunization-based methods used in the discovery of antibodies and other research tools "The autonomous lab reflects the kind of progress Danaher is uniquely positioned to deliver," said Julie Sawyer Montgomery, President and Chief Executive Officer of Danaher. "By applying our science, technology and culture of continuous improvement, we can help turn promising ideas into validated systems faster. It is an important step toward a future where AI, automation and intelligent systems dramatically accelerate the journey from discovery to impact."

Based at Abcam, a Danaher company, the lab uses AI to help create new affinity reagents, including antibodies, then builds and tests each one, feeding every result back into the model to improve the next design. The lab brings together industry-leading technologies and expertise from several Danaher operating companies, including Beckman Coulter Life Sciences, Cytiva, Genedata, Integrated DNA Technologies, and Molecular Devices, in one connected workflow. The device orchestration and robotic automation is the result of collaborative work with Automata*. This continuous design-make-test-learn loop can run in a fraction of the time it takes today, without trading speed for scientific rigor. This approach applies the same test-and-verify discipline of continuous improvement long used across Danaher operations to an AI-enabled laboratory environment. The lab is set to be an early proof point for how Danaher's smart instruments, AI-ready data, and expert agentic systems can accelerate scientific discovery and medical progress.

"This lab represents a new model for scientific discovery, where AI, automation and human expertise work together in a continuous learning cycle," said JC Gutierrez-Ramos, Senior Vice President and Chief Science Officer of Danaher. "Speed is what supercharges that cycle. Every result sharpens the next design, so the faster each loop runs, the faster discovery compounds. The lab is designed to deliver up to eight times faster progress from idea to validated reagent and up to a tenfold increase in reagent generation, while scientists continue to make the key decisions. That frees them to focus on the complex scientific challenges where human insight matters most."

The lab is an example of a broader program across Danaher intended to create a fleet of smart instruments that are easier to integrate and control programmatically, produce AI-ready data, and include expert-level agentic systems designed to simplify operation, improve data quality and generate deeper insights. These intelligent devices can then be connected to create integrated workflows and autonomous labs that execute design-make-test-learn cycles. The approach also supports a shift toward more predictive and standardized research workflows, with models helping prioritize the most promising designs before they are made and robotics supporting more consistent experimentation.

The platform reflects an important milestone in the Company's continued investment in connected science at a global scale: technologies designed to help researchers move from scientific question to validated answer with greater speed, consistency and confidence.

FORWARD-LOOKING STATEMENTS AND OTHER INFORMATION
Statements in this release that are not strictly historical, including statements regarding the Company's AI-powered autonomous lab, the anticipated timing, performance, capabilities and benefits of the platform, the development and deployment of smart instruments, integrated workflows and autonomous labs, and the expected impact of these technologies on biomedical research and scientific discovery, and any other statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward-looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things: the impact of the tariffs and related actions implemented by the U.S. and other countries, the impact of our debt obligations (including debt we have incurred to finance the acquisition of Masimo Corporation) on our operations and liquidity, deterioration of or instability in the global economy, the markets we serve and the financial markets, uncertainties with respect to the development, deployment, and use of artificial intelligence in our business and products, the impact of global health crises, uncertainties relating to national laws or policies, including laws or policies to protect or promote domestic interests and/or address foreign competition, our ability to successfully identify and consummate appropriate acquisitions and strategic investments, our ability to integrate the businesses we acquire and achieve the anticipated growth, synergies and other benefits of such acquisitions, contingent liabilities and other risks relating to acquisitions, investments, strategic relationships and divestitures (in each case, including with respect to our acquisition of Masimo), including tax-related and other contingent liabilities relating to past and future IPOs, split-offs or spin-offs, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including rules relating to off-label marketing and other regulations relating to medical devices and the health care industry), the results of our clinical trials and perceptions thereof, our ability to effectively address cost reductions and other changes in the health care industry, security breaches or other disruptions of our information technology systems or violations of data privacy laws, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, changes in tax laws applicable to multinational companies, litigation, regulatory proceedings and other contingent liabilities including intellectual property and environmental, health and safety matters, the rights of the United States government with respect to our production capacity in times of national emergency or with respect to intellectual property/production capacity developed using government funding, risks relating to product, service or software defects, product liability and recalls, risks relating to our manufacturing operations, the impact of climate change, legal or regulatory measures to address climate change and other sustainability topics and our ability to address regulatory requirements or stakeholder expectations relating to climate change and other sustainability topics, risks relating to fluctuations in the cost and availability of the supplies we use (including commodities) and labor we need for our operations, our relationships with and the performance of our channel partners, uncertainties relating to collaboration arrangements with third-parties, the impact of deregulation on demand for our products and services, labor matters and our ability to recruit, retain and motivate talented employees, U.S. and non-U.S. economic, political, geopolitical, legal, compliance, social and business factors (including the impact of elections, regulatory and policy changes or uncertainty, government shutdowns and military conflicts such as the conflict in the Middle East), disruptions and other impacts relating to man-made and natural disasters, inflation and the impact of our By-law exclusive forum provisions. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our 2025 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the second quarter of 2026. These forward-looking statements speak only as of the date of this release and except to the extent required by applicable law, the Company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.

ABOUT DANAHER
Danaher is a leading global life sciences and diagnostics innovator, committed to advancing the power of science and technology to improve human health. Through our connected ecosystem of industry-leading businesses, we work side by side with customers to solve many of their most complex scientific and clinical challenges—accelerating the moment scientific discovery becomes human impact. Powered by the Danaher Business System, our advanced science and technology and proven ability to innovate help enable faster, more accurate diagnoses and reduce the time, cost, and risk required to discover, develop, and deliver life-changing therapies. Through continuous improvement and operational excellence, our approximately 60,000 associates worldwide are focused on delivering lasting impact and improving quality of life around the world, while building a healthier, more sustainable tomorrow. That's Innovation at the speed of life. Explore more at www.danaher.com.

*Automata received an investment from DHR in Jan 2026

SOURCE Danaher Corporation

Si829x platform with ProVCD™ technology moves from development to pre-production release for EV traction inverters  | Source: Skyworks Solutions, Inc.

IRVINE, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Skyworks Solutions, Inc. (Nasdaq: SWKS), an innovator of high-performance analog and mixed-signal semiconductors, today announced that its Si829x isolated safety gate driver with ProVCD™ technology has completed AEC-Q100 automotive qualification and is ready for advanced prototyping. Samples, tools, user guides, and application notes are available now. Designed for scalable, high-performance inverter architectures, the Si829x supports both SiC FETs and IGBTs while helping customers improve efficiency, simplify system design, and reduce system cost in applications ranging from automotive drivetrains to safety-critical electric vertical take-off and landing (eVTOL) systems.

AEC-Q100 Qualified and Ready for Evaluation

With AEC-Q100 qualification completed, the Si829x is now positioned to support customers for initial product evaluation through pre-production prototypes. Samples are available today, giving customers a qualified, prototype-ready path to design-in.

The Si829x was designed to support customer functional safety system designs rated up to ASIL D, subject to system-level implementation and validation, to deliver the robustness required for EV traction inverters and other safety critical motor control applications. Its integrated protection features include:

Extensive diagnostic fault coverage, notification and managementComprehensive safety mechanisms including power-up self-checks and safe state enforcement – a functional safety manual is available todayAdvanced isolation technology certified by multiple independent organizations for enhanced safety and reliability With applications in battery electric vehicles, hybrid electric vehicles, eAgriculture, eTrucking, robotaxis, and exciting new segments like eVTOL aircraft, Si829x is a comprehensive choice among isolated gate drivers for safety-critical advanced propulsion systems.

Full Documentation and Development Tools Now Available

Alongside qualification, Skyworks has prepared the complete technical resource set for the Si829x, including datasheet, technical reference manual, functional safety manual and application notes. This resource set, available under NDA, gives design teams comprehensive technical documentation to evaluate, integrate and validate the part.

Skyworks has also released customer-facing development tools, including two evaluation board kits, companion GUI software and complex device driver (CDD) software, designed to shorten development cycles and reduce time-to-market.

A New Approach to Gate Drive Control

Unlike conventional voltage-mode gate drivers, the Si829x uses ProVCD™, which is Skyworks’ second-generation variable current drive that delivers high resolution gate waveform shaping and cycle-by-cycle control through a digital interface. This approach enables:

Precise 15 Amp 3-phase turn-on and turn-off current waveform controlSwitching-loss reductions of up to 44% in Skyworks testing, compared with voltage-mode gate driveReduced electromagnetic interference (EMI) and filtering requirementsImproved thermal efficiency through multiple packaging optionsSmaller PCB footprint and potential system-level cost savings Together, these benefits allow manufacturers to increase inverter efficiency while simplifying system design and accelerating development cycles.

“Si829x gives customers a qualified path from evaluation to advanced prototypes,” said Mario Battello, vice president of product line management at Skyworks. “The ProVCD™ platform combines software-configurable performance with the safety, isolation and design flexibility needed to standardize inverter designs for EVs, eVTOL, and eAgriculture, and accelerate development for high power motor applications like datacenter cooling and AI power supplies.”

Platform Scalability and Design Flexibility

The Si829x is designed as a configurable platform, allowing engineers to adjust gate drive parameters through software rather than fixed hardware components. This configurability supports:

Design reuse across multiple vehicle platformsFaster development and validation cyclesGreater flexibility to optimize performance, efficiency and costVendor-agnostic compatibility across power semiconductor technologies By supporting both SiC FETs and IGBTs within a single gate driver platform that integrates a VPOS regulator, bipolar gate drive voltages are provided without the need for additional, external bias supplies.

Si829x availability

The Si829x platform is now available for sampling. To learn more, including product features, package options and design resources, visit skyworks.com/go/si829x.

About Skyworks

Skyworks® is a global leader in high-performance RF, precision timing, power management and mixed-signal solutions that power the intelligent, connected world. Through deep engineering expertise, Skyworks helps customers address rising complexity and deliver seamless connectivity across smartphones, vehicles, networks and critical infrastructure.

From defense and aerospace systems to the connected edge, AI infrastructure and next-generation automotive platforms, Skyworks provides the essential technologies that connect, synchronize and power physical AI, as intelligence moves out of the data center and into the real world. Harnessing decades of technical leadership and trusted partnerships across the technology ecosystem, Skyworks helps the world's leading innovators bring next-generation products and services to market.

Skyworks is a member of the S&P 500® market index (Nasdaq: SWKS). For more information, please visit www.skyworks.com.

Safe Harbor Statement

Any forward-looking statements contained in this press release are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include without limitation information relating to future events, results and expectations of Skyworks. Forward-looking statements can often be identified by words such as “anticipates,” “expects,” “forecasts,” “intends,” “believes,” “plans,” “may,” “will” or “continue,” and similar expressions and variations or negatives of these words. Actual events and/or results may differ materially and adversely from such forward-looking statements as a result of certain risks and uncertainties including, but not limited to, our ability to timely and accurately predict market requirements and evolving industry standards and to identify opportunities in new markets; our ability to develop, manufacture, and market innovative products and avoid product obsolescence; our ability to compete in the marketplace and achieve market acceptance of our products; the level of widespread deployment or adoption of commercial 5G networks, AI and other new technologies; the availability and pricing of third-party semiconductor foundry, assembly and test capacity, raw materials and supplier components; the quality of our products; our products’ ability to perform under stringent operating conditions; and other risks and uncertainties identified in the “Risk Factors” section of Skyworks' most recent Annual Report on Form 10-K (and/or Quarterly Report on Form 10-Q) as filed with the Securities and Exchange Commission (“SEC”). Copies of Skyworks' SEC filings can be obtained, free of charge, on Skyworks' website (www.skyworksinc.com) or at the SEC's website (www.sec.gov). Any forward-looking statements contained in this press release are made only as of the date hereof, and we undertake no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.

Note to Editors: ProVCD™, SelVCD™, Skyworks and the Skyworks symbol are trademarks or registered trademarks of Skyworks Solutions, Inc., or its subsidiaries in the United States and other countries. Third-party brands and names are for identification purposes only and are the property of their respective owners.

Media Relations:        
Constance Griffiths
(949) 230-4867        
[email protected] Relations:
Raji Gill
(949) 508-0973
[email protected]        

The Trade Desk (TTD -0.50%) was the wrong kind of busy in September. The next-generation adtech company didn't look like a business primed for the future after announcing a restructuring plan, witnessing a rival score a high-profile client, and being booted from a major stock index, among other setbacks.

Last month was a blustery one full of headwinds for The Trade Desk, so perhaps it's lucky to have exited September with "only" an 11% decline in its share price. Yet I think it could go lower. Before we get to that, however, let's recap the company's not-so-good month.

Image source: Getty Images.

Restructurings and roadblocksSeptember didn't start on an encouraging note for The Trade Desk. Numerous media outlets, citing a company statement, reported that it planned to cut its workforce by roughly 15% as part of a broader restructuring effort. The company effectively confirmed this in a regulatory filing, in which it estimated that such moves would result in charges of around $39 million to $51 million, offset by a reversal of approximately $4 million to $5 million in stock-based compensation. There was clearly some urgency to this for The Trade Desk, as it expressed a desire to complete the process by the beginning of the third quarter (i.e., the start of October).

Also, early in the month, The Trade Desk was removed from the benchmark S&P 500 index. In a quarterly rebalancing by the index's operator, S&P Dow Jones Indices, the company's stock was shifted to the S&P SmallCap 600 Index. Such was the effect of a shrinking price and, therefore, market cap, on the beaten-down stock.

As if these body blows weren't enough, its rival Amazon (AMZN +1.95%) Ads announced a new advertising partnership with top artificial intelligence (AI) developer OpenAI. Under its terms, Amazon Ads clients will have the option to expand their campaigns into conversational experiences using OpenAI's ChatGPT model. Amazon added that select advertisers, which it did not name, were testing this service in a pilot program.

Finally, at the end of the month, industry website Ad Exchanger published a story stating that The Trade Desk was unable to serve ads to Apple's (AAPL +0.22%) Safari browser in certain instances. The problem, apparently, was the tech company's iOS 27, the latest iteration of its operating system. Ad Exchanger said Apple was investigating the issue. As of this writing, the situation had not been resolved.

Premium Feature

Moneyball Superscore

90/100

Today's Change

(

1.95

%) $

4.89

Current Price

$

256.29

A September not to rememberThe Trade Desk has shown resiliency in the past, so I wouldn't underestimate its ability to rebound. Yet that seemingly urgent restructuring project indicates a company scrambling to avoid trouble, and Amazon Ads looks like it might be a tough competitor with abundant resources. It doesn't feel to me like The Trade Desk has a sufficient moat, so it's vulnerable. I believe we might not be seeing the bottom for this stock yet.

More than 175 biotechs use pre-configured applications to streamline operations

, /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that more than 175 emerging biotechs are establishing a technology foundation with Veeva Basics. Biotechs are launching pre-configured and pre-validated Veeva Basics applications in weeks, adding systems that can scale as they move from startup to commercialization. Veeva Basics delivers unified, end-to-end applications for clinical, regulatory, quality, medical, and commercial, enabling high-growth companies to speed innovation while saving time, effort, and cost.

"As a growing company with under 40 employees, we're focused on developing science fast to deliver antibody-drug conjugates (ADCs) that target difficult-to-treat cancers," said Bryan Ball, chief technology operations officer at Whitehawk Therapeutics. "Our partnership with Veeva helped us replace paper processes with industry-leading solutions without an IT team or complex customizations. Veeva Basics redefined how we operate, significantly improving processes across regulatory and quality for greater speed and compliance."

Biotechs are leveraging Veeva Basics to drive new ways of working, including shifting regulatory publishing strategies from outsourced to insourced. Veeva Submissions Publishing Basics provides a modern application for submission building and health authority interactions that equips regulatory teams to bring publishing in-house. For biotechs preparing to publish their first submissions to the FDA, Veeva Basics enables them to hit critical regulatory milestones with improved visibility and control across the entire regulatory lifecycle.

"Insourcing our submission publishing through Veeva Basics gave us sharper quality control and significantly faster regulatory timelines," said Darryl Clarke, global head, regulatory operations at Structure Therapeutics. "We have modern applications with global support to execute quickly now, and the flexibility to scale in the future."

"Biotechs are responsible for so much of the innovation shaping the industry and they need technology that reflects the pace that they operate in," said Jim Thai, vice president, Veeva Basics. "It's been a privilege to work with industry pioneers and build this community of Veeva Basics customers advancing drug development."

Built on the proven Vault Platform, Veeva Basics applications help customers to scale their technology infrastructure seamlessly as they grow. For more on Veeva Basics, visit veevabasics.com, or register for Veeva R&D and Quality Summit, Oct. 20-21 in Boston. The event is open exclusively to life sciences industry professionals.

About Veeva Systems
Veeva delivers the industry cloud for life sciences with applications, agents, data, and consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.

Veeva Forward-Looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the fiscal year ended July 31, 2026, which you can find here (a summary of risks which may impact our business can be found on pages 33 and 34), and in our subsequent SEC filings, which you can access at sec.gov.

SOURCE Veeva Systems

Orders supports customer's second AI processor program on Sonoma, with production expected to ramp in calendar 2027

FREMONT, CA / ACCESS Newswire / October 7, 2026 / Aehr Test Systems (NASDAQ:AEHR), a leading provider of test and burn-in solutions for semiconductor devices used in artificial intelligence (AI), silicon photonics, data center, automotive, and industrial applications, today announced approximately $6 million in follow-on production orders from its lead hyperscale customer for package-level burn-in (PLBI) of its next-generation AI processor for data center training and inference applications.

The orders include additional Sonoma™ high-power package-level test and burn-in systems, fully turnkey burn-in modules (BIMs) and device-specific sockets, as well as production software enhancements. The systems and consumables will be deployed at one of the customer's outsourced semiconductor assembly and test (OSAT) partners in Taiwan. Deliveries under the order are scheduled over the next six months.

This next-generation AI processor is the second from this customer to use Aehr's Sonoma platform for production burn-in. Following the previously announced initial production win, these orders expand the customer's capacity ahead of an expected production ramp of this second AI device in calendar 2027. The customer has indicated that this second AI processor is expected to ultimately reach production volumes exceeding those of the customer's first processor brought into production burn-in on the Sonoma platform. That first processor is already in high-volume production, with volumes expected to continue ramping significantly as additional Sonoma system capacity is deployed over the next several months.

"These follow-on production orders demonstrate the continued expansion of our relationship with this hyperscale customer and its confidence in Sonoma to support successive generations of increasingly powerful and complex AI processors," said Gayn Erickson, President and Chief Executive Officer of Aehr Test Systems. "The program is progressing from qualification and initial production systems to additional systems, consumables and software supporting the anticipated production ramp. As volumes increase, we believe there is potential for significant additional demand for Sonoma systems and device-specific consumables."

The next-generation processor requires independently controlled thermal zones within each package to achieve the operating conditions needed for effective production burn-in and early-life failure screening. Sonoma's multi-zone thermal control capabilities enable independent temperature management across different areas of a device while delivering the high current required to electrically stress the processor.

The platform also supports independent electrical test vectors and monitoring of multiple devices or functional elements within a multi-chip package. These capabilities address the differing power densities and thermal characteristics of advanced AI packages, which increasingly combine compute die, high-bandwidth memory and interface components.

"As AI processors become more complex, controlling the temperature of the package as a whole is no longer sufficient for some applications," Erickson continued. "Sonoma's ability to independently manage multiple thermal zones and electrical test functions helps customers address these challenges. We believe these capabilities will become increasingly important as AI packages continue to grow in power, size, complexity and value."

Aehr is also engaged in detailed discussions with this customer regarding reliability qualification and production burn-in requirements for future generations of higher-power, larger AI devices. These discussions include both Aehr's Sonoma package-level and FOX-XP™ wafer-level burn-in (WLBI) platforms.

"As the value of advanced AI packages increases, identifying early-life failures before expensive packaging can deliver significant economic benefits," Erickson added. "WLBI can screen die before assembly, while PLBI can stress and screen the completed device. Customers may choose either approach or use both at different stages of qualification and production, depending on their requirements."

"Our ability to support both approaches positions Aehr well as customers develop reliability strategies for future AI processors. With Sonoma supporting this customer's first processor in high-volume production and now its next-generation program, we are building a foundation for continued growth as the customer's AI roadmap advances."

About Aehr Test Systems

Headquartered in Fremont, California, Aehr Test Systems is a leading provider of test solutions for testing, burning-in, and stabilizing semiconductor devices in wafer-level, singulated die, and package-level form, and has installed thousands of systems worldwide. Increasing quality, reliability, safety, and security needs of semiconductors used across multiple applications, including electric vehicles, electric vehicle charging infrastructure, solar and wind power, computing, advanced artificial intelligence (AI) processors, data and telecommunications infrastructure, and solid-state memory and storage, are driving additional test requirements, incremental capacity needs, and new opportunities for Aehr's products and solutions. Aehr has developed and introduced several innovative products including the FOX-PTM families of test and burn-in systems and FOX WaferPakTM Aligner, FOX WaferPak Contactor, FOX DiePak® Carrier and FOX DiePak Loader. The FOX-XP and FOX-NP systems are full-wafer contact and singulated die/module test and burn-in systems that can test, burn-in, and stabilize a wide range of devices such as leading-edge silicon carbide-based and other power semiconductors, 2D and 3D sensors used in mobile phones, tablets, and other computing devices, memory semiconductors, processors, microcontrollers, systems-on-a-chip, and photonics and integrated optical devices. The FOX-CP system is a low-cost single-wafer compact test solution for logic, memory and photonic devices and the newest addition to the FOX-P product family. The FOX WaferPak Contactor contains a unique full-wafer contactor capable of testing wafers up to 300mm that enables IC manufacturers to perform test, burn-in, and stabilization of full wafers on the FOX-P systems. The FOX DiePak Carrier allows testing, burning in, and stabilization of singulated bare die and modules up to 1024 devices in parallel per DiePak on the FOX-NP and FOX-XP systems up to nine DiePaks at a time. Acquired through its acquisition of Incal Technology, Inc., Aehr's new line of high-power package-level reliability/burn-in test solutions for AI semiconductor manufacturers, including its high-power Sonoma family of test solutions for AI accelerators, GPUs, and high-performance computing (HPC) processors, position Aehr within the rapidly growing AI market as a turnkey provider of reliability and testing that span from engineering to high volume production. For more information, please visit Aehr Test Systems' website at www.aehr.com.

Safe Harbor Statement

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally relate to future events or Aehr's future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as "may," "will," "should," "expects," "plans," "anticipates," "going to," "could," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "potential," or "continue," or the negative of these words or other similar terms or expressions that concern Aehr's expectations, strategy, priorities, plans, or intentions. Forward-looking statements in this press release include, but are not limited to, future requirements and orders of Aehr's new and existing customers; Aehr's ability to receive orders and generate revenue in the future, as well as Aehr's beliefs regarding the factors impacting the foregoing, including the growth of the markets referred to herein; Aehr's ability to integrate Incal efficiently; and the timing and extent to which the acquisition is accretive. The forward-looking statements contained in this press release are also subject to other risks and uncertainties, including those more fully described in Aehr's recent Form 10-K, 10-Q and other reports filed from time to time with the Securities and Exchange Commission. Aehr disclaims any obligation to update information contained in any forward-looking statement to reflect events or circumstances occurring after the date of this press release.

# # #

SOURCE: Aehr Test Systems